• Markets
  • icon
  • Companies
BIT · ASX

Biotron Limited (ASX:BIT)

AU$0.054

 0.002 (3.846%)
ASX:Live
22/05/2024 04:10:12 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

BIT Overview

BIT Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About BIT

Telephone

Address

Description

Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.

BIT Price Chart

Key Stats

Market Cap

AU$46.92M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.12

Trade Value (12mth)

AU$65,583.00

1 week

-5.26%

1 month

-20.59%

YTD

-41.94%

1 year

92.86%

All time high

0.4309679865837097

Key Fundamentals

EPS 3 yr Growth

-18.900%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-152.50%

ROIC

-161.90%

Interest Coverage

-1,138.20

Quick Ratio

4.20

Other Data

Shares on Issue (Fully Dilluted)

902m

HALO Sector

Next Company Report Date

29-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

BIT Announcements

Latest Announcements

Date Announcements

26 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

05 April 24

POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV

×

POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV

27 March 24

Response to ASX Price Query

×

Response to ASX Price Query

27 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

08 February 24

$1.64M R&D rebate received

×

$1.64M R&D rebate received

30 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

14 December 23

Shareholder Update

×

Shareholder Update

01 December 23

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

27 November 23

Notification of cessation of securities - BIT

×

Notification of cessation of securities - BIT

27 November 23

Change of Director's Interest Notice MM

×

Change of Director's Interest Notice MM

22 November 23

Presentation to Annual General Meeting

×

Presentation to Annual General Meeting

22 November 23

Results of AGM

×

Results of AGM

10 November 23

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

27 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

26 October 23

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

24 October 23

Presentation to Investors

×

Presentation to Investors

20 October 23

Annual Report/Notice of Annual General Meeting/Proxy Form

×

Annual Report/Notice of Annual General Meeting/Proxy Form

10 October 23

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

29 September 23

Response to ASX Price Query

×

Response to ASX Price Query

26 September 23

Letter to Shareholders

×

Letter to Shareholders

11 September 23

Response to ASX Price Query

×

Response to ASX Price Query

25 August 23

Full Year Statutory Accounts and Appendix 4E

×

Full Year Statutory Accounts and Appendix 4E

25 August 23

Corporate Governance Statement

×

Corporate Governance Statement

25 August 23

Appendix 4G

×

Appendix 4G

16 August 23

COMPLETION OF PHASE 2 COVID CLINICAL TRIAL

×

COMPLETION OF PHASE 2 COVID CLINICAL TRIAL

BIT Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.0 13.6 -13.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.1 13.3 -3.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.3 -5.7 -15.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 -71.7 133.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 725 725 821 Lock Lock Lock
Basic m Lock Lock Lock Lock 725 725 821 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 4 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.6 4.4 4.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -3 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.8 36.0 -82.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -3 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.6 35.6 -81.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -3 -5 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.7 12.9 -25.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -2 -3 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 6 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -2 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 28.6 -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 4 2 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 4 2 4 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -4 -2 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 1 3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 1 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 -70.6 180.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -73.8 -145.9 -84.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -79.3 -110.3 -229.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -58.9 -111.3 -161.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -62.9 -97.5 -152.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -3,385.9 -541.5 -1,138.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 0.6 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -108.8 -152.3 -124.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 9.4 2.3 4.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 9.4 2.3 4.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.8 98.8 98.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -755.2 -324.5 -344.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -73.8 -145.9 -84.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.7 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -82.7 -254.6 -110.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,728.2 1,811.4 2,510.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,728.2 -1,811.4 -2,510.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

BIT Shortsell

Frequently Asked Questions

The current share price of Biotron Limited (BIT:ASX) is AU$0.054.
The 52-week high share price for Biotron Limited (BIT:ASX) is AU$0.12.
The 52-week low share price for Biotron Limited (BIT:ASX)? is AU$0.02.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) has a franking level of 0.0%.
Biotron Limited (BIT:ASX) is classified in the Healthcare.
The current P/E ratio for Biotron Limited (BIT:ASX) is .